1045703-73-8

Basic information

• Product Name: 3-amino-5-phenyl-2-selenophenecarbonitrile
• Synonyms: 3-amino-5-phenyl-2-selenophenecarbonitrile
• CAS NO: 1045703-73-8
• Molecular Weight: 247.158
• Mol File: 1045703-73-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-amino-5-phenyl-2-selenophenecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-phenyl-2-selenophenecarbonitrile(1045703-73-8)
• EPA Substance Registry System: 3-amino-5-phenyl-2-selenophenecarbonitrile(1045703-73-8)

Safety Data

• Hazardous Substances Data: 1045703-73-8(Hazardous Substances Data)

Upstream product

• 78583-84-3 3-chloro-3-phenylprop-2-enenitrile 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 1045703-85-2 9-amino-2-phenyl-5,6,7,8-tetrahydroselenopheno[3,2-b]quinoline 
• 1045703-79-4 8-amino-2-phenyl-6,7-dihydro-5H-cyclopenta[b]selenopheno[2,3-e]pyridine 
• 1045703-91-0 10-amino-2-phenyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]selenopheno[2,3-e]pyridine 
• 1252925-91-9 3-amino-5-phenylselenophene-2-carboxamide 
• 1202167-17-6 4-chloro-6-phenylselenolo[3,2-d][1,2,3]triazine 
• 1170315-24-8 6-phenylselenolo[3,2-d]pyrimidin-4-one 

Relevant articles and documents

SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic

ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Synthesis of selenophene analogues of the tacrine series: Comparison of classical route and microwave irradiation

New 3-amino-2-selenophenecarbonitriles condensed with cyclanones to afford, in one step, analogues of Tacrine. A comparison between classical heating and microwave irradiation for the Friedlaender condensation is presented. Georg Thieme Verlag Stuttgart.